Andrea Wartenberg‐Demand

775 total citations
20 papers, 427 citations indexed

About

Andrea Wartenberg‐Demand is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Andrea Wartenberg‐Demand has authored 20 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Andrea Wartenberg‐Demand's work include Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (6 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Andrea Wartenberg‐Demand is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (6 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Andrea Wartenberg‐Demand collaborates with scholars based in Germany, United States and Poland. Andrea Wartenberg‐Demand's co-authors include Kenneth C. Anderson, Nikhil C. Munshi, Sundar Jagannath, Todd M. Zimmerman, Sagar Lonial, Asher Chanan‐Khan, Leonard T. Heffner, Robert J. Lutz, Leonard T. Heffner and Jacalyn Rosenblatt and has published in prestigious journals such as Blood, Annals of the Rheumatic Diseases and European Journal of Neuroscience.

In The Last Decade

Andrea Wartenberg‐Demand

17 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrea Wartenberg‐Demand Germany 11 209 188 147 114 88 20 427
Samantha Hol Netherlands 11 251 1.2× 116 0.6× 126 0.9× 139 1.2× 449 5.1× 16 736
Anja Löffler Germany 5 393 1.9× 42 0.2× 325 2.2× 342 3.0× 267 3.0× 7 745
David Stroncek United States 9 233 1.1× 36 0.2× 151 1.0× 19 0.2× 109 1.2× 18 455
Cassandra E. Burnett United States 6 225 1.1× 36 0.2× 130 0.9× 21 0.2× 209 2.4× 9 451
Luca De Maso Italy 10 44 0.2× 25 0.1× 178 1.2× 59 0.5× 141 1.6× 16 464
P.G.M. Bloemen Netherlands 8 35 0.2× 31 0.2× 134 0.9× 49 0.4× 130 1.5× 11 454
Michelle Ryan Ireland 9 33 0.2× 108 0.6× 131 0.9× 20 0.2× 85 1.0× 11 354
John D. Jeppson United States 11 177 0.8× 21 0.1× 120 0.8× 49 0.4× 290 3.3× 16 483
Julia Meier Germany 9 70 0.3× 46 0.2× 226 1.5× 12 0.1× 48 0.5× 19 348
Г. В. Селедцова Russia 12 137 0.7× 18 0.1× 92 0.6× 25 0.2× 252 2.9× 51 433

Countries citing papers authored by Andrea Wartenberg‐Demand

Since Specialization
Citations

This map shows the geographic impact of Andrea Wartenberg‐Demand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Wartenberg‐Demand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Wartenberg‐Demand more than expected).

Fields of papers citing papers by Andrea Wartenberg‐Demand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Wartenberg‐Demand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Wartenberg‐Demand. The network helps show where Andrea Wartenberg‐Demand may publish in the future.

Co-authorship network of co-authors of Andrea Wartenberg‐Demand

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Wartenberg‐Demand. A scholar is included among the top collaborators of Andrea Wartenberg‐Demand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Wartenberg‐Demand. Andrea Wartenberg‐Demand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Singer, Mervyn, Antoní Torres, Andrea Wartenberg‐Demand, et al.. (2023). The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial. Critical Care. 27(1). 436–436. 7 indexed citations
2.
Devlieger, Roland, Horst Buxmann, Gerardo Nigro, et al.. (2021). Serial Monitoring and Hyperimmunoglobulin versus Standard of Care to Prevent Congenital Cytomegalovirus Infection: A Phase III Randomized Trial. Fetal Diagnosis and Therapy. 48(8). 611–623. 14 indexed citations
3.
Schmidt, Carolin, et al.. (2021). The Dual Role of a Polyvalent IgM/IgA-Enriched Immunoglobulin Preparation in Activating and Inhibiting the Complement System. Biomedicines. 9(7). 817–817. 10 indexed citations
4.
Schmidt, Julia, Andrea Wartenberg‐Demand, & Simon Forstmeier. (2021). Pferdegestützte Biografiearbeit für Erwachsene (PBA-E). 13(3).
5.
Schmidt, Julia C., Andrea Wartenberg‐Demand, & Simon Forstmeier. (2020). Equine-assisted biographical work (EABW) with individuals in the second half of life: study protocol of a multicentre randomised controlled trial. Trials. 21(1). 857–857.
6.
Jagannath, Sundar, Leonard T. Heffner, Sikander Ailawadhi, et al.. (2019). Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(6). 372–380. 67 indexed citations
7.
Vollenhoven, Ronald van, Edward Keystone, Vibeke Strand, et al.. (2018). Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases. 77(4). 495–499. 9 indexed citations
8.
Kelly, Kevin R., David S. Siegel, Asher Chanan‐Khan, et al.. (2016). Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 128(22). 4486–4486. 44 indexed citations
9.
Welte, Tobias, R. Phillip Dellinger, Henning Ebelt, et al.. (2015). Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation – The CIGMA study. Respiratory Medicine. 109(6). 758–767. 27 indexed citations
10.
11.
12.
13.
Buxmann, Horst, Wolfgang Kamin, Gergely Kriván, et al.. (2012). An open-label, randomized efficacy and safety trial of subcutaneous and intramuscular BT088 (Fovepta) human hepatitis B immunoglobulin in neonates of HBV-carrier mothers. Journal of Perinatal Medicine. 40(4). 433–438.
14.
Heffner, Leonard T., Sundar Jagannath, Todd M. Zimmerman, et al.. (2012). BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity. Blood. 120(21). 4042–4042. 50 indexed citations
15.
Jagannath, Sundar, Asher Chanan‐Khan, Leonard T. Heffner, et al.. (2011). BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 118(21). 305–305. 41 indexed citations
16.
Jagannath, Sundar, Asher Chanan‐Khan, Leonard T. Heffner, et al.. (2010). BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 116(21). 3060–3060. 10 indexed citations
17.
Trollmo, Christina, Christian Becker, Helmut Jonuleit, et al.. (2010). (1125) - Selective Activation of Naturally Occurring Regulatory T Cells (Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers of Clinical Activity and Early Phase II Results in Patients with Rheumatoid Arthritis (RA). 4 indexed citations
18.
Chanan‐Khan, Asher, Sundar Jagannath, Leonard T. Heffner, et al.. (2009). Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.. Blood. 114(22). 1862–1862. 18 indexed citations
19.
Gramowski, Alexandra, Konstantin Jügelt, G.P. McGregor, et al.. (2006). Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips. European Journal of Neuroscience. 24(2). 455–465. 55 indexed citations
20.
Wartenberg‐Demand, Andrea, et al.. (2003). Efficacy of a triple herbal preparation in mild depressive disorders: results of a randomised placebo‐controlled trial. Focus on Alternative and Complementary Therapies. 8(4). 551–552. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samantha Hol Breakdown of academic impact, for papers by Anja Löffler Breakdown of academic impact, for papers by David Stroncek Breakdown of academic impact, for papers by Cassandra E. Burnett Breakdown of academic impact, for papers by Luca De Maso Breakdown of academic impact, for papers by P.G.M. Bloemen Breakdown of academic impact, for papers by Michelle Ryan Breakdown of academic impact, for papers by John D. Jeppson Breakdown of academic impact, for papers by Julia Meier Breakdown of academic impact, for papers by Г. В. Селедцова
Rankless by CCL
2026